Dose-Effect Response to Targeted Radionuclide Therapy

This intensive 1,5-day course bridges the gap between radiobiology, dosimetry, and clinical practice in targeted radionuclide therapy. Designed for early-career nuclear medicine physicians and medical physicists, the programme explores dose-response relationships in the three most commonly used theranostic molecules: somatostatin-ligands for neuroendocrine tumours, PSMA-inhibitors for prostate cancer, and radioiodine for thyroid malignancies.

Through a balanced faculty of radiobiologists, dosimetry experts, and experienced nuclear medicine physicians, participants will gain practical insights into the biological effects of radiation, dosimetry calculation methodologies, and their clinical implementation. The course emphasizes hands-on learning through joint case sessions, interactive workshops, and patient-specific treatment planning exercises.

Format: Lectures, case discussions, interactive workshops, and panel sessions

At the end of the two days, participants of the course will be able to:

• Explain the fundamental radiobiological principles underlying dose-effect relationships in targeted radionuclide therapy and how they differ from external beam radiotherapy and brachytherapy.
• Describe the complete workflow from imaging acquisition to dose calculation and apply core dosimetry concepts to clinical TRT scenarios.
• Integrate dosimetry data into clinical decision-making for patient selection, treatment planning, and outcome prediction in targeted radionuclide therapy.
• Compare and contrast the clinical applications, dose-response characteristics, and dosimetric considerations for somatostatin-ligand therapy (neuroendocrine tumours), PSMA-inhibitor therapy (prostate cancer), and radioiodine therapy (thyroid disease).
• Interpret key clinical trial outcomes and evidence-based data related to dosimetry-guided TRT across the three major theranostic applications.
• Design a patient-specific TRT treatment plan incorporating radiobiological principles, dosimetric calculations, and clinical considerations for organ protection and tumour targeting.
• Identify the practical challenges and solutions for implementing dosimetry protocols in routine clinical nuclear medicine practice.
• Critically evaluate when and how personalized dosimetry can optimize therapeutic outcomes and minimize toxicity in individual patients.

Early-career nuclear medicine doctors and medical physicists